期刊文献+

^(99m)Tc-甲氧异腈显像在分化型甲状腺癌转移灶诊断中的临床应用 被引量:2

The clinical application of ^(99m)Tc-MIBI imaging to diagnosis metastatic lesions of differentiated thyroid carcinoma
下载PDF
导出
摘要 目的:探讨^(99m)Tc-甲氧异腈(MIBI)显像在分化型甲状腺癌(DTC)转移灶诊断中的临床应用价值。方法:72例接受131I治疗的分化型甲状腺癌随访患者,以甲状腺球蛋白增高阈值>10ng/ml为标准分为实验组(n=35)和对照组(n=37),常规行131I全身扫描(WBS),同时以^(99m)Tc-MIBI作为显像剂行核素肿瘤显像。以核素显像感兴趣区(ROI)技术,测定放射性(T/NT)比值,进行半定量分析;比较^(99m)Tc-MIBI显像及131I全身显像在诊断甲状腺癌转移灶灵敏性、特异性、准确性上的差异。结果:实验组,^(99m)Tc-MIBI显像和131I全身显像T/NT比值分别为3.24±0.43和5.35±0.32,有明显差异;对照组T/NT比值分别为1.31±0.18和1.26±0.25,无明显差异;两种方法诊断分化型甲状腺癌转移灶的灵敏性、特异性、准确性分别为24.52%、64.28%、32.83%和92.45%、57.14%、85.07%。结论:^(99m)Tc-MIBI显像诊断分化型甲状腺癌转移灶灵敏性及准确性均低于131I全身显像,特异性无明显差异,但99mTc-MIBI显像可作为131I全身显像阴性分化型甲状腺癌随访方法的有益补充。 Objective: To evaluate application value of^99mTc-MIBI imaging in diagnosis of differentiated thyroid carcinoma metastatic lesions.Methods: Seventy-two patients with differentiated thyroid cancer after^131 I nuclear therapy were divided into experiment group and control group depended on Tg(the judgement threshold value is 10ng/ml).All lesions were confirmed by ^131I-WBS and/or^99mTc-MIBI imaging or by other imaging modalities.The ratio of tumor to normal tissue(T/NT) was calculated over ROI to observe the radioactive uptake.All scintigraphically detected lesions were confirmed by histopathological analysis.Results: The T/NT ratios were 3.24 ± 0.43 and 5.35 ±0.32 in experiment group,respectively,1.31 ± 0.18 and 1.26 ± 0.25 in control group,respectively.The sensitivity,specificity and accuracy in differentiating malignant from benign lesion was 24.52%,64.28%,32.83% and 92.45%,57.14%,85.07%,respectively.Conclusion:^99mTc-MIBI imaging sensitivity,specificity were lower than ^131 I whole body imaging in diagnosis of differentiated thyroid carcinoma metastatic lesions,but^99mTc-MIBI scintigraphy can be used as an effective complement to ^131I-WBS negative of differentiated thyroid cancer conventional methods.
出处 《现代肿瘤医学》 CAS 2017年第8期1289-1291,共3页 Journal of Modern Oncology
基金 陕西省科技厅自然科学基金项目(编号:2012JM4009)
关键词 分化型甲状腺癌 ^99MTC-甲氧基异丁基异腈 ^131I全身扫描 differentiated thyroid carcinoma 99mTc-MIBI 131I-WBS
  • 相关文献

参考文献6

二级参考文献54

  • 1赖非云,张诠,陈福进,郭朱明,吴秋良,侯景辉,卿菁.p53和Rb与甲状腺乳头状癌分化程度关系的研究[J].中华肿瘤防治杂志,2006,13(12):920-922. 被引量:3
  • 2叶千春,王淑侠,乔穗宪,唐安戊,何建军.^(99)Tc^m-MIBI甲状腺显像鉴别甲状腺结节良恶性再认识[J].中华核医学杂志,2006,26(4):209-210. 被引量:16
  • 3Cooper DS, Doherty GM, Haugen BR, et aI. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid, 2009,19(11) :1167-1214.
  • 4Favia G, Iacobonc M. Zanclla S, et al. Managemenl ofinvasive and advanced lhyroid cancer[J]. Mincrwi Endocrinol. 2009, 34 (1):37- 55.
  • 5Maxon H R. Detedion of residual and recurrent thyroid cancer by radionuclide imaging.[J]. Thyroid,1999,9(5):443-446.
  • 6Iwata M, Kasagi K, Misaki T, et al. Comparison of whole body ISF FDG PET, ^99mTc-M1BI SPET, and post therapeutic ^131Ⅰ-Na scintigraphy in the detection of metastatic tyroid cancer[J]. Eur J Nucl Med Mol Imaging,200d,31(4):491-498.
  • 7Ng D C, Sundram F X, Sin A E. ^99mTc-sestamibi and ^131Ⅰ whohc-body scintigraphy and initial serum thyroglobulln in the management of differenlialed thyroid carcinoma [ J ]. J Nucl Med, 2000, 41 ( 4 ) : 631-635.
  • 8Miyamoto S, Kasagi K, Misaki T, et al. Evaluation of tcchneti um-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma[J].J Nucl Med,1997,38(3):352-356.
  • 9Sundram F X, Goh A S, Ang E S. Role of technetium-99m ses- tamibi in Iocalisation of thyroid cancer metastases[J]. Ann Acad Med Singapore,1993,22(4) :557-559.
  • 10Dadparvar S, Chevres A, Tulchinsky M, et al. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentia ted thyroid careinoma: comparison with thallium 201 and iodine 131 Na scintigraphy, and serum thyroglobulin quantitation[J]. EurJ Nucl Med,1995,22(11):1330-1338.

共引文献43

同被引文献16

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部